Anti-CTLA-4 mAb strongly reduces the proportion of Tregs in the TME from the murine melanoma tumor model (B16), whereas, in human tumors, the TA-Tregs proportion does not seem significantly impacted. This evidence concerns the gene CTLA4 and neoplasm.